FLT3 and acute myeloid leukemia: Other large studies have also confirmed that the presence of MRG and NPM1 mutations, in the absence of FLT3-ITD, does not alter the favorable prognoses and treatment outcomes of patients with NPM1-mutated AML [97,98].